Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026493 · ClinicalTrials.gov registry record · Phase 1
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
A Phase 1 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 257
- Enrollment target
NCT01026493 is a Phase 1 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 257 participants.
The verdict
NCT01026493, a Phase 1 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 257 participants
- Enrollment target
Study Summary
RATIONALE: Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide. work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with temozolomide may kill more tumor cells. PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of giving veliparib together with temozolomide and to see how well it works in treating patients with recurrent glioblastoma.
Interventions
- DRUG temozolomide 60 mg x 21 days
- DRUG temozolomide 75 mg x 21 days
- DRUG ABT-888 20 mg x 21 days
- DRUG ABT-888 40 mg x 21 days
- DRUG Temozolomide 150 mg x 5 days
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2010-07 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01026493
The ClinicalTrials.gov registry entry for NCT01026493 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 257 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which temozolomide 60 mg x 21 days is the first listed.
NCT01026493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01026493 about?
NCT01026493 is a clinical study titled "Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma". RATIONALE: Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide. work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib ...
What is the current status of trial NCT01026493?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 257 participants. The study started on 2010-07. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01026493?
The interventions under investigation include: temozolomide 60 mg x 21 days (DRUG), temozolomide 75 mg x 21 days (DRUG), ABT-888 20 mg x 21 days (DRUG), ABT-888 40 mg x 21 days (DRUG), Temozolomide 150 mg x 5 days (DRUG).
Who is sponsoring clinical trial NCT01026493?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.